DEADLINE ALERT for LVS, IPHA, JPM, and FAF: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
06 nov. 2020 11h00 HE
|
The Law Offices of Frank R. Cruz
LOS ANGELES, Nov. 06, 2020 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Innate Pharma, JPMorgan, First American Financial, and BMW and Encourages Investors to Contact the Firm
04 nov. 2020 20h00 HE
|
Bragar Eagel & Squire
NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
ROSEN, A LEADING LAW FIRM, Files First Securities Class Action Lawsuit Against Innate Pharma S.A.; Encourages Investors with Losses in Excess of $100K to Contact the Firm – IPHA
26 oct. 2020 18h00 HE
|
The Rosen Law Firm PA
NEW YORK, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Innate...
INNATE PHARMA ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Innate Pharma S.A. and Encourages Investors to Contact the Firm
26 oct. 2020 18h00 HE
|
Bragar Eagel & Squire
NEW YORK, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United...
INNATE PHARMA ALERT: Bragar Eagel & Squire, P.C. is Investigating Innate Pharma S.A. on Behalf of Innate Stockholders and Encourages Investors to Contact the Firm
23 oct. 2020 20h00 HE
|
Bragar Eagel & Squire
NEW YORK, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Innate Pharma S.A....
U.S. Food and Drug Administration Lifts Partial Clinical Hold on Lacutamab TELLOMAK Trial in Advanced T-Cell Lymphomas
24 juin 2020 01h00 HE
|
INNATE PHARMA
Innate Pharma to re-activate TELLOMAK trial in the US New GMP-certified batch has been successfully manufactured Conference call to be held today on the lacutamab clinical trial program ...
Innate Pharma annonce la présentation de données cliniques sur IPH5401 et monalizumab au congrès de l’ESMO 2019
23 sept. 2019 01h00 HE
|
INNATE PHARMA
INNATE PHARMA ANNONCE LA PRÉSENTATION DE DONNÉES CLINIQUES SUR IPH5401 ET MONALIZUMAB AU CONGRÈS DE L’ESMO 2019 Données préliminaires issues de STELLAR-001, l’étude de Phase I en escalade de dose...
Innate Pharma announces clinical data presentations on IPH5401 and monalizumab at ESMO 2019
23 sept. 2019 01h00 HE
|
INNATE PHARMA
INNATE PHARMA ANNOUNCES CLINICAL DATA PRESENTATIONS ON IPH5401 AND MONALIZUMAB AT ESMO 2019 Preliminary results of IPH5401 STELLAR-001, a dose escalation Phase I study in patients with advanced solid...
Innate Pharma présente ses résultats financiers et l’avancée de son portefeuille au premier semestre 2019
13 sept. 2019 01h00 HE
|
INNATE PHARMA
INNATE PHARMA PRÉSENTE SES RÉSULTATS FINANCIERS ET L’AVANCÉE DE SON PORTEFEUILLE AU PREMIER SEMESTRE 2019 Démarrage de l’essai clinique multicohorte de Phase II d’IPH4102 (TELLOMAK) ; La cohorte...
Innate Pharma reports first half 2019 financial results and business update
13 sept. 2019 01h00 HE
|
INNATE PHARMA
INNATE PHARMA REPORTS FIRST HALF 2019 FINANCIAL RESULTS AND BUSINESS UPDATE Initiation of multi-cohort IPH4102 Phase II clinical trial (TELLOMAK) Sézary Syndrome cohort designed to be pivotal;...